Introduction {#Sec1}
============

In recent years, our knowledge about the pathophysiology of migraine has improved leading to the concept that the disease, typically expressed by episodic manifestations, is, actually, a chronic, and in a subgroup of patients, progressive disorder. Many authors indicated that the disease could lead to anatomic and functional changes in the central nervous system \[[@CR1]\].

In patients with migraine, a preventive therapy should reduce frequency and severity of attacks in order to reduce acute medication use, to improve quality of life and to reduce the risk of progression to a chronic form. Bigal and Lipton \[[@CR2]\] explained mechanisms of migraine progression from different points of view: clinical, physiological, and anatomic. They also proposed a model to address bidirectional migraine transitions from one form to another (i.e., low frequency episodic migraine, high frequency episodic migraine, chronic migraine-CM) with transition rates modelled as a function of demographic, environmental and genetic risk factors. Among risk factors, migraine frequency and acute medication overuse are believed as important targets contributing to the transformation from episodic to chronic migraine.

Topiramate is a neuromodulator approved for the use in epilepsy and migraine prevention in USA and in many European and world markets. In the present review, we summarize the most reliable hypothesis concerning pathophysiology of migraine, topiramate mechanisms of action, moreover we discuss its role in preventing and treating chronic migraine.

Pathophysiology {#Sec2}
===============

Cortical spreading depression (CSD), discovered by Leão in 1944 \[[@CR3]\], is implicated in the pathogenesis of migraine headaches \[[@CR4], [@CR5]\]. CSD is characterized by a slowly spreading wave of neuronal and glial depolarization lasting approximately 1 min that develops within brain areas such as cerebral cortex, cerebellum, or hippocampus after electrical or chemical stimulation. The pivotal event in the generation and propagation of CSD is a marked decrease of neuronal membrane resistance associated with a massive increase in extracellular K^+^ and an increase in intracellular Na^+^ and Ca^2+^. Various stimuli trigger CSD including direct cortical trauma, exposure to high concentrations of excitatory amino acids or K^+^, direct electrical stimulation, inhibition of Na^+^/K^+^-ATPase, and energy failure.

A link between CSD and migraine pathogenesis has been hypothesized for more than 40 years \[[@CR4]--[@CR7]\]. Many recent studies using magnetoencephalography or highfield strength, high-resolution magnetic resonance imaging (MRI) established a link between migraine aura and CSD \[[@CR8], [@CR9]\].

An interesting possibility is that CSD or CSD-like events may also play a role in the pathophysiology of migraine without aura (MWoA), perhaps after CSD is generated within brain regions that are clinically silent \[[@CR10]\].

A number of recent studies in migraineurs \[[@CR11], [@CR12]\] show subclinical structural brain changes, going from progressive cellular damage in nociceptive systems to diffuse white matter (WM) loss, multifocal WM lesions, and ischemic stroke. They found these changes only in a small subset of patients. A study with Diffusion Tension Imaging (DTI), more sensitive than conventional MRI, detects subtle WM changes that are not necessarily ischemic \[[@CR13]\]. In this study, Granziera and colleagues demonstrated that cortical and subcortical structures involved in motion perception differ from migraineurs and people without migraine. Chronic dysfunction of these areas may explain interictal findings of motion processing deficits in migraineurs, whereas episodic dysfunction might contribute to the initiation of an attack. Data indicate that structural changes are present in cortical regions in migraine patients, even outside attacks, that migraine with aura (MWA) and MWoA shares the same abnormalities, and that the changes are present in areas where CSD most probably develops. It seems likely that MWA and MWoA are two phenotypes sharing a common pathophysiological substrate and that asymptomatic CSD may occur in some patients.

The finding of morphometric changes in the brains of migraineurs may be of fundamental importance because migraine has so far been considered a condition with abnormal brain function but completely normal brain structure.

Chronic systemic treatment with migraine prophylactic drugs suppresses CSD as a potential explanation of their efficacy in migraine prophylaxis. Using two complementary paradigms, Ayata \[[@CR10]\] showed that chronic treatment with topiramate, valproate, propranolol, amitriptyline, or methysergide rendered rat cerebral cortex more resistant to CSD and longer treatments produced stronger CSD inhibition.

The risk of developing chronic headache appears, at least in part, linked to heredity and genetics. The relative risk for developing chronic daily headache (CDH) in first-degree relatives was found to be 2.1--3.9 times greater than the known risk within the general population \[[@CR14]\]. Hypotheses for the pathogenesis of CM have included conditions of low central neuronal serotonin (5-HT), disregulation of neuronal 5-HT receptors, hyperexcitability of central pain pathways, low central *β*-endorphin levels, and dysfunction of NMDA receptors \[[@CR15]\]. There are several lines of evidence to suggest that repeated episodes of migraine headache are associated with changes in CNS structure or function. Through specialized (MRI) brain imaging techniques, Welch and colleagues \[[@CR1]\] demonstrated abnormal non-heme iron deposition in the periaqueductal gray matter of the rostral brainstem in migraineurs but not in control subjects. The amount of iron deposited was positively correlated with the subjects' lifetime duration of migraine. It was hypothesized that these structural changes occur through iron-catalyzed free radical cell damage "accentuated by repeated episodes of hyperoxia" during migraine attacks. These findings suggest that repeated attacks of migraine result in iron accumulation in the antinociceptive systems of the brainstem, potentially causing or acting as a marker for impaired pain modulation.

Clinical observations and a growing body of evidence indicate that chronic headache is associated with persistent hyperalgesia and allodynia \[[@CR16]\]. It has been hypothesized that prolonged nociceptive input might not only incite sensitization of central pain pathways but also cause neural plasticity in these pathways by promoting the transformation of episodic headache to chronic forms of headache \[[@CR15]\]. This hypothesis appears to be supported by recent epidemiological and clinic-based studies that sought to identify risk factors for this phenotypic transformation of headache presentation. Headache frequency was found to be an important and substantial risk factor for headache transformation \[[@CR17]\]. A baseline headache frequency of four to five headache days per month was identified as a threshold for initiating an exponential increase in the risk of transformation from episodic headache to chronic forms, including CM \[[@CR18]\]. These findings can imply that reduction in migraine attack severity, through aggressive use of acute migraine treatments, and decrease of migraine frequency with preventive migraine treatments may reduce the risk of neural plasticity and consequential transformation to a more chronic, refractory, and disabling migraine pattern. Acute medication overuse is also considered an important risk factor leading to the development of CM. Among patients affected by CM, acute medication overuse is about 30--50% and it is estimated that the medication overuse increases the risk of migraine progression sevenfold.

Mechanisms of action {#Sec3}
====================

Topiramate \[2,3:4,5-Bis-*O*-(1-methylethylidene)-β-[d]{.smallcaps}-fructopyranose sulfamate\] is a sulfamate-substituted monosaccaride, derived from [d]{.smallcaps}-fructose. Several molecular activities have been identified for topiramate: inhibitory effects on voltage-gated Na^+^ and Ca^2+^ channels, modulation of glutamate-mediated neurotransmission (reducing depolarization induced by AMPA and kainate mediated currents), enhancement of some types of GABA~A~ receptors, inhibition of carbonic anhydrase (CA); other less established mechanisms of action have been proposed, such as modulation of K^+^ conductance and proteins regulating neurotransmitter release from synaptic terminals \[[@CR19]\]. In brief, the drug reduces excitatory neurotransmission and enhances inhibitory neurotransmission, both probably involved in the pathophysiology of migraine. Topiramate, through a broad profile of action, might act at different levels: reducing nociceptive transmission through trigeminovascular modulation, and inhibiting cortical spreading depression \[[@CR20], [@CR21]\].

The role of topiramate in migraine prevention {#Sec4}
=============================================

Several large, randomized, placebo-controlled trials have proven topiramate to be effective for migraine prevention in adults \[[@CR22]--[@CR24]\], with 100 mg/day being the target dose. Demonstration of efficacy was based on reduction in migraine frequency and use of acute medication, improvement of quality of life evaluated by the Migraine Specific Questionnaire (MSQ) and the Short-Form36 (SF36). The benefits appear after the first month of treatment and persist throughout the subsequent 6-month treatment period. Data from the open-label extension of pivotal trials and a successive randomized, placebo-controlled long-term study showed that benefits were sustained with prolonged treatment up to 12--14 months \[[@CR25], [@CR26]\].

Based on the analysis of a large database of \>1,500 patients included in four randomised, double-blind, placebo-controlled trials, topiramate was generally safe and reasonably well tolerated in migraine prevention \[[@CR27]\]. Most common adverse events (AE) associated with topiramate were mild or moderate in severity and occurred more frequently during titration. Paresthesia was the most common AE (35, 51, and 49% at 50, 100, and 200 mg/die, respectively) which appeared to be self-limiting and not typically leading to drug discontinuation. Unlike other preventive treatments, topiramate was not associated with weight gain but rather with weight loss (67% of patients with topiramate vs. 19% with placebo).

Prevention of migraine progression {#Sec5}
==================================

A pooled analysis of data from the three pivotal trials suggested that preventive therapy with topiramate 100 mg/day may reduce the risk of progression to chronic forms of headache \[[@CR18]\]. This analysis shows that topiramate reduces the risk of an increase in headache rate; specifically, patients at higher risk of developing CM (those with ≥12 headache days at baseline) appeared to benefit most from topiramate therapy. Furthermore, topiramate reduced the use of acute medication, particularly in patients with high frequency of migraine at baseline.

Data from open-label studies \[[@CR28], [@CR29]\] and one small placebo-controlled trial \[[@CR30]\] suggested topiramate to be useful also in CM.

More recently, two multicenter, randomized, double-blind, placebo controlled trials, one performed in the USA and the other one in Europe, both published in 2007, demonstrated that topiramate is effective and safe also in patients affected by CM, in the presence or absence of medication overuse, and/or of other migraine prophylaxis \[[@CR31], [@CR32]\]. An integrated review of these studies was recently published by Silberstein and colleagues \[[@CR33]\] describing differences in patient populations and in the classification of CM between the US and European trials. However, the key difference was the absence of limitation in acute medication intake, which allowed the European trial to demonstrate extended benefit of topiramate also to the subgroup of patients complicated by medication overuse.

Conclusion {#Sec6}
==========

Based on American and European guidelines \[[@CR34], [@CR35]\], the goals of a preventive treatment are to reduce frequency and severity of attacks, to improve response to acute therapy, to reduce use of acute medications, to limit disability, and to improve quality of life. When clinicians choose the best treatment for a patient they have to consider different aspects such as frequency of attacks, contraindications to therapies, adverse effects, and comorbidities.

Recent evidence suggests that migraine preventive treatment may also reduce the risk of transformation of episodic migraine to chronic headache. Therefore, a prophylaxis treatment should be initiated early once patients with risks of progression, i.e., elevated migraine frequency and/or frequent acute medication intake, have been identified.

Topiramate, by acting positively on both these risk factors may prevent the development of CM. Furthermore, topiramate is effective in the treatment of patients already progressed to CM and difficult-to-treat conditions associated with medication overuse.

Based on its wide spectrum of mechanisms of action, topiramate may exert its effect in migraine prevention by reducing nociceptive transmission through trigeminovascular modulation, and inhibiting neuronal hyperexcitability, which affects initiation and development of CSD.

Topiramate represents an additional therapeutic option that is able to act at different levels of the migraine cycle: reduction of frequency in episodic migraine, prevention, and treatment of CM.

None.
